Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C β inhibitor, ruboxistaurin

Journal of Diabetes and its Complications

Volumn 22, Issue 2, 2008, Pages 88-95

  Brooks, Belinda ^a   Delaney Robinson, Carol ^b   Molyneaux, Lynda ^a   Yue, Dennis K ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Diabetic peripheral neuropathy; Endothelium; Microvascular blood flow; Neurovascular response; Ruboxistaurin

Indexed keywords

ACETYLCHOLINE; NITROPRUSSIDE SODIUM; PLACEBO; PROTEIN KINASE C BETA INHIBITOR; RUBOXISTAURIN;

ACTION POTENTIAL; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROPHYSIOLOGY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; LINEAR REGRESSION ANALYSIS; MALE; MICROVASCULARIZATION; MULTICENTER STUDY; NERVE CONDUCTION; NERVE FIBER C; NEUROLOGIC EXAMINATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL NEUROPATHY; PERONEUS NERVE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SKIN BLOOD FLOW; STATISTICAL SIGNIFICANCE; SURAL NERVE; SYMPTOM; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; BLOOD FLOW VELOCITY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; ELECTROPHYSIOLOGY; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; MALE; MALEIMIDES; MICROCIRCULATION; MIDDLE AGED; NEURAL CONDUCTION; PROTEIN KINASE C; REGRESSION ANALYSIS; SKIN;

EID: 38949186057     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2007.07.002     Document Type: Article

References (55)

1. Aronin N., Leeman S.E., and Clements R.S. Diminished flare response in neuropathic diabetic patients. Comparison of effects of substance P, histamine, and capsaicin. Diabetes 36 (1987) 1139-1143
2. Arora S., Smakowski P., Frykberg R.G., Simeone L.R., Freeman R., LoGerfo F.W., and Veves A. Differences in foot and forearm skin microcirculation in diabetic patients with and without neuropathy. Diabetes Care 21 (1998) 1339-1344
3. Bastyr E.J., Price K.L., Bril V., and The MBBQ Study Group. Development and validity testing of the Neuropathy Total Symptom Score-6: Questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clinical Therapeutics 27 (2005) 1278-1294
4. Beckman J.A., Goldfine A.B., Gordon M.B., Garrett L.A., and Creager M.A. Inhibition of protein kinase C beta prevents impaired endothelium-dependent vasodilation caused by hyperglycemia in humans. (see comment). Circulation Research 90 (2002) 107-111
5. Beggs J., Johnson P.C., Olafsen A., and Watkins C.J. Innervation of the vasa nervorum: Changes in human diabetics. Journal of Neuropathology and Experimental Neurology 51 (1992) 612-629
6. Bridges D., Thompson S.W., and Rice A.S. Mechanisms of neuropathic pain. British Journal of Anaesthesia 87 (2001) 12-26
7. Brownlee M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 54 (2005) 1615-1625
8. Cameron N.E., Cotter M.A., Jack A.M., Basso M.D., and Hohman T.C. Protein kinase C effects on nerve function, perfusion, Na(+), K(+)-ATPase activity and glutathione content in diabetic rats. Diabetologia 42 (1999) 1120-1130
9. Cameron N.E., Eaton S.E., Cotter M.A., and Tesfaye S. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44 (2001) 1973-1988
10. Candido R., and Allen T.J. Haemodynamics in microvascular complications in type 1 diabetes. Diabetes/Metabolism Research Reviews 18 (2002) 286-304
11. Caselli A., Rich J., Hanane T., Uccioli L., and Veves A. Role of C-nociceptive fibers in the nerve axon reflex-related vasodilation in diabetes. Neurology 60 (2003) 297-300
12. Dyck P.J., Litchy W.J., Lehman K.A., Hokanson J.L., Low P.A., and O'Brien P.C. Variables influencing neuropathic endpoints: The Rochester Diabetic Neuropathy Study of Healthy Subjects. (see comment). Neurology 45 (1995) 1115-1121
13. Flynn M.D., and Tooke J.E. Diabetic neuropathy and the microcirculation. Diabetic Medicine 12 (1995) 298-301
14. Giannini C., and Dyck P.J. Basement membrane reduplication and pericyte degeneration precede development of diabetic polyneuropathy and are associated with its severity. Annals of Neurology 37 (1995) 498-504
15. Gilbert R.E., Kim S.A., Tuttle K.R., Bakris G.L., Toto R.D., McGill J.B., Haney D.J., Kelly D.J., and Anderson P.W. Effect of ruboxistaurin on urinary transforming growth factor-{beta} in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care 30 (2007) 995-996
16. Hamdy O., Abou-Elenin K., LoGerfo F.W., Horton E.S., and Veves A. Contribution of nerve-axon reflex-related vasodilation to the total skin vasodilation in diabetic patients with and without neuropathy. Diabetes Care 24 (2001) 344-349
17. Hermenegildo C., Felipo V., Minana M.D., and Grisolia S. Inhibition of protein kinase C restores Na+,K(+)-ATPase activity in sciatic nerve of diabetic mice. Journal of Neurochemistry 58 (1992) 1246-1249
18. Hermenegildo C., Felipo V., Minana M.D., Romero F.J., and Grisolia S. Sustained recovery of Na(+)-K(+)-ATPase activity in sciatic nerve of diabetic mice by administration of H7 or calphostin C, inhibitors of PKC. Diabetes 42 (1993) 257-262
19. Khan F., Elhadd T.A., Greene S.A., and Belch J.J. Impaired skin microvascular function in children, adolescents, and young adults with type 1 diabetes. Diabetes Care 23 (2000) 215-220
20. Kihara M., and Low P.A. Impaired vasoreactivity to nitric oxide in experimental diabetic neuropathy. Experimental Neurology 132 (1995) 180-185
21. Kilo S., Berghoff M., Hilz M., and Freeman R. Neural and endothelial control of the microcirculation in diabetic peripheral neuropathy. Neurology 54 (2000) 1246-1252
22. Malik R.A., Newrick P.G., Sharma A.K., Jennings A., Ah-See A.K., Mayhew T.M., Jakubowski J., Boulton A.J., and Ward J.D. Microangiopathy in human diabetic neuropathy: Relationship between capillary abnormalities and the severity of neuropathy. Diabetologia 32 (1989) 92-102
23. Malik R.A., Tesfaye S., Thompson S.D., Veves A., Sharma A.K., Boulton A.J., and Ward J.D. Endoneurial localisation of microvascular damage in human diabetic neuropathy. Diabetologia 36 (1993) 454-459
24. Malik R.A., Veves A., Masson E.A., Sharma A.K., Ah-See A.K., Schady W., Lye R.H., and Boulton A.J. Endoneurial capillary abnormalities in mild human diabetic neuropathy. Journal of Neurology, Neurosurgery and Psychiatry 55 (1992) 557-561
25. Maxfield E.K., Cameron N.E., and Cotter M.A. Effects of diabetes on reactivity of sciatic vasa nervorum in rats. Journal of Diabetes and Its Complications 11 (1997) 47-55
26. McGill J.B., King G.L., Berg P.H., Price K.L., Kles K.A., Bastyr E.J., and Hyslop D.L. Clinical safety of the selective PKC-beta inhibitor, ruboxistaurin. Expert Opinion on Drug Safety 5 (2006) 835-845
27. Nakamura J., Kato K., Hamada Y., Nakayama M., Chaya S., Nakashima E., Naruse K., Kasuya Y., Mizubayashi R., Miwa K., Yasuda Y., Kamiya H., Ienaga K., Sakakibara F., Koh N., and Hotta N. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 48 (1999) 2090-2095
28. Naruse K., Rask-Madsen C., Takahara N., Ha S.-W., Suzuma K., Way K.J., Jacobs J.R.C., Clermont A.C., Ueki K., Ohshiro Y., Zhang J., Goldfine A.B., and King G.L. Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitric oxide synthase function in obesity-associated insulin resistance. Diabetes 55 (2006) 691-698
29. Obrosova I.G. Update on the pathogenesis of diabetic neuropathy. Current Diabetes Reports 3 (2003) 439-445
30. Olney R.K. Clinical trials for polyneuropathy: The role of nerve conduction studies, quantitative sensory testing, and autonomic function testing. Journal of Clinical Neurophysiology 15 (1998) 129-137
31. Olney R.K. Neurophysiologic evaluation and clinical trials for neuromuscular diseases. (comment). Muscle & Nerve 21 (1998) 1365-1367
32. Parkhouse N., and Le Quesne P.M. Impaired neurogenic vascular response in patients with diabetes and neuropathic foot lesions. New England Journal of Medicine 318 (1988) 1306-1309
33. Pitei D.L., Watkins P.J., and Edmonds M.E. NO-dependent smooth muscle vasodilatation is reduced in NIDDM patients with peripheral sensory neuropathy. Diabetic Medicine 14 (1997) 284-290
34. PKC-DMES Study Group. Effect of ruboxistaurin in patients with diabetic macular edema: Thirty-month results of the randomized PKC-DMES clinical trial. Archives of Ophthalmology 125 (2007) 318-324
35. PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: Initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54 (2005) 2188-2197
36. PKC-DRS2 Study Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113 (2006) 2221-2230
37. Quattrini C., Harris N.D., Malik R.A., and Tesfaye S. Impaired skin microvascular reactivity in painful diabetic neuropathy. Diabetes Care 30 (2007) 655-658
38. Rendell M., Bergman T., O'Donnell G., Drobny E., Borgos J., and Bonner R.F. Microvascular blood flow, volume, and velocity measured by laser Doppler techniques in IDDM. Diabetes 38 (1989) 819-824
39. Setter S.M., Campbell R.K., and Cahoon C.J. Biochemical pathways for microvascular complications of diabetes mellitus. Annals of Pharmacotherapy 37 (2003) 1858-1866
40. Sheetz M.J., and King G.L. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288 (2002) 2579-2588
41. Stansberry K.B., Peppard H.R., Babyak L.M., Popp G., McNitt P.M., and Vinik A.I. Primary nociceptive afferents mediate the blood flow dysfunction in non-glabrous (hairy) skin of type 2 diabetes: A new model for the pathogenesis of microvascular dysfunction. Diabetes Care 22 (1999) 1549-1554
42. Tandan R., Skljarevski V., Price K., Kles K., Bastyr E., and for the Ruboxistaurin Treatment of DPN Study Group. Neuropathy progression in patients with symptomatic diabetic peripheral neuropathy: Experience from phase 3 ruboxistaurin clinical trials. Neurology 66 (2006) A191
43. Tesfaye S., Harris N., Jakubowski J.J., Mody C., Wilson R.M., Rennie I.G., and Ward J.D. Impaired blood flow and arterio-venous shunting in human diabetic neuropathy: A novel technique of nerve photography and fluorescein angiography. (see comment). Diabetologia 36 (1993) 1266-1274
44. Tesfaye S., Malik R., Harris N., Jakubowski J.J., Mody C., Rennie I.G., and Ward J.D. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycaemic control (insulin neuritis). Diabetologia 39 (1996) 329-335
45. Tesfaye S., Skljarevski V., Price K.L., Kles K., Bastyr E.J., and for the Ruboxistaurin Study Group. Marked placebo effect at the end of a 1-year, clinical trial: Clues to the nature of symptoms in diabetic peripheral neuropathy?. Diabetes 55 (2006) A191
46. Tuck R.R., Schmelzer J.D., and Low P.A. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 107 (1984) 935-950
47. Tuttle K.R., Bakris G.L., Toto R.D., McGill J.B., Hu K., and Anderson P.W. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28 (2005) 2686-2690
48. Veves A., Akbari C.M., Primavera J., Donaghue V.M., Zacharoulis D., Chrzan J.S., DeGirolami U., LoGerfo F.W., and Freeman R. Endothelial dysfunction and the expression of endothelial nitric oxide synthetase in diabetic neuropathy, vascular disease, and foot ulceration. Diabetes 47 (1998) 457-463
49. Vinik A.I., Bril V., Kempler P., Litchy W.J., Tesfaye S., Price K.L., Bastyr E.J., and The MBBQ Study Group. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clinical Therapeutics 27 (2005) 1164-1180
50. Vinik A.I., Erbas T., Park T.S., Pierce K.K., and Stansberry K.B. Methods for evaluation of peripheral neurovascular dysfunction. Diabetes Technology & Therapeutics 3 (2001) 29-50
51. Vinik A.I., Erbas T., Park T.S., Stansberry K.B., Scanelli J.A., and Pittenger G.L. Dermal neurovascular dysfunction in type 2 diabetes. Diabetes Care 24 (2001) 1468-1475
52. Way K.J., Katai N., and King G.L. Protein kinase C and the development of diabetic vascular complications. Diabetic Medicine 18 (2001) 945-959
53. Westerman R.A., Widdop R.E., Hannaford J., Low A., Roberts R.G., Kent P., Sideris K., Yip T., Hales J.R., and Stephens F.R. Laser Doppler velocimetry in the measurement of neurovascular function. Australasian Physical & Engineering Sciences in Medicine 11 (1988) 53-66
54. Woolf C.J., and Mannion R.J. Neuropathic pain: Aetiology, symptoms, mechanisms, and management. (see comment). Lancet 353 (1999) 1959-1964
55. Yasuda H., and Dyck P.J. Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy. Neurology 37 (1987) 20-28